12 month, multi-center, open-label, prospective, randomized, parallel group study investigating a standard regimen in de novo kidney transplant patients versus a Certican based regimen either in combination with Cyclosporin A or Tacrolimus

Trial Profile

12 month, multi-center, open-label, prospective, randomized, parallel group study investigating a standard regimen in de novo kidney transplant patients versus a Certican based regimen either in combination with Cyclosporin A or Tacrolimus

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Everolimus (Primary) ; Basiliximab; Ciclosporin; Mycophenolate mofetil; Mycophenolic acid; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms ATHENA
  • Sponsors Novartis Pharma
  • Most Recent Events

    • 27 Sep 2017 12-month safety and efficacy results, presented at the 18th Congress of the European Society for Organ Transplantation
    • 27 Sep 2017 Results (n=612) from month 12 on infections and CMV-/ BKV-events presented at the 18th Congress of the European Society for Organ Transplantation
    • 21 Sep 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top